key: cord-0697701-y0t8kp5o
authors: Huang, Yu-Feng; Bai, Chen; He, Fan; Xie, Ying; Zhou, Hua
title: Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)
date: 2020-05-21
journal: Pharmacol Res
DOI: 10.1016/j.phrs.2020.104939
sha: 7ed9bbb1fce003cbcfa646b53e9a9fa7144141a5
doc_id: 697701
cord_uid: y0t8kp5o

[Figure: see text] The Coronavirus Disease 2019 (COVID-19) has been declared as a global pandemic, but specific medicines and vaccines are still being developed. In China, interventional therapies with traditional Chinese medicine for COVID-19 have achieved significant clinical efficacies, but the underlying pharmacological mechanisms are still unclear. This article reviewed the etiology of COVID-19 and clinical efficacy. Both network pharmacological study and literature search were used to demonstrate the possible action mechanisms of Chinese medicines in treating COVID-19. We found that Chinese medicines played the role of antivirus, anti-inflammation and immunoregulation, and target organs protection in the management of COVID-19 by multiple components acting on multiple targets at multiple pathways. AEC2 and 3CL protein could be the direct targets for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Quercetin, kaempferol, luteolin, isorhamnetin, baicalein, naringenin, and wogonin could be the main active ingredients of Chinese medicines for the management of COVID-19 by targeting on AEC2 and 3CL protein and inhibiting inflammatory mediators, regulating immunity, and eliminating free radicals through COX-2, CASP3, IL-6, MAPK1, MAPK14, MAPK8, and REAL in the signaling pathways of IL-17, arachidonic acid, HIF-1, NF-κB, Ras, and TNF. This study may provide meaningful and useful information on further research to investigate the action mechanisms of Chinese medicines against SARS-CoV-2 and also provide a basis for sharing the “China scheme" for COVID-19 treatment.

Therefore, TCM is a valuable resource for drug discovery against In China, the treatment protocol of COVID-19 emphasizes the combination of TCM with conventional therapy. [11] The current practice has demonstrated that TCM intervention is essential and effective in the management of COVID-19, showing by the improvement of the cure rate, shortened disease course, delayed disease progression, and reduced mortality rate. [12] [13] It was reported that the overall effective rate reached over 90% in 74187 confirmed COVID-19 cases who received TCM treatment.

[14] Lou [15] reported that the change of hematology is positive in COVID-19 patients treated with TCM. A prospective multicenter open-label randomized controlled trial also confirmed the efficacy of Lianhua Qingwen capsule in ameliorating the clinical symptoms of COVID-19 patients, including fever, fatigue, and cough. [16] Several retrospective and controlled clinical studies have also reported that TCM treatment effectively improved the fever, sweating, cough, headache, shortness of breath, chest distress, nausea, and diarrhea in COVID-19 patients. [17] [18] [19] [20] The chest radiogram has been improved significantly as well. [21] The levels of ESR, CRP, and IL-6 were significantly decreased, and the level of IFN-γ was increased in the group received both (Table 1 and Fig. 1) ; the detailed mechanisms were described below.

According to the literature [61] [62] [63] , angiotensin-converting enzyme 2 (ACE2) and 3Clike protease (3CL pro) can be the critical targets for antiviral drug design. CMs could target ACE2 to prevent SARS-CoV-2 from entering into host cells or target 3CL pro to inhibit the replication and assembly of the virus in cells.

Li [46] reported that the Lianhua Qinwen capsule significantly and dose-dependently inhibited the replication of SARS-CoV-2 with an IC50 value of 411.2 μg/mL in Vero E6 cells that were infected with 100 TCID50 of SARS-CoV-2 using cytopathic effect and plaque reduction assay. The number of virions of cells treated with Lianhua Qinwen capsule at 600 μg/mL was significantly reduced compared with that of control cells under the transmission electron microscope. Wang [47] , Ling [48] and Ye [49] J o u r n a l P r e -p r o o f speculated that quercetin, kaempferol, luteolin, aloe-emodin, rutin, forsythoside E, and hyperoside in Lianhua Qinwen could be the active ingredients in inhibiting SARS- [42] screened out licorice glycoside E, naringenin, robinin, kaempferol, (2R)-7hydroxy-2-(4-hydroxyphenyl) chroman-4-ketone, quercetin, isorhamnetin and irisolidone from Huoxiang Zhengqi as potential 3CL pro inhibitors, which could inhibit SARS-CoV-2 replication by targeting on PIK3CG and E2F1 through PI3K-Akt signaling pathway. Besides, based on traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) and literatures, SHI [51] constructed and analyzed the mechanisms of Xuebijing injection and found rosmarinic acid in this injection could inhibit the virus replication through PI3K-Akt signal pathway as well.

Simayi [43] and Shen [44] 

Virus-infected alveolar cells release signals to recruit and activate immune cells. These immune cells secrete a variety of cytokines and chemokines to recruit more immune cells to the lesion site. The activated immune cells destroy the virus by releasing inflammatory mediators and phagocytosis. However, the excessive immune responses initiate a "cytokine storm", which causes many immune cells and secretions in the lungs of COVID-19 patients. Cytokine storm alters vascular permeability, blocks airways, causes edema, hypoxia, and target organ damage, etc. The occurrence of cytokine storm in patients with COVID-19 is an essential cause of exacerbation and even death. [64, 65] CMs can play a regulatory role in the causes, processes, and other aspects of the cytokine storm by modulating the release of cytokines, the functions of macrophages, monocytes and neutrophils, the permeability of pulmonary vessels, and the activities of T cells. [ Shen [44] and Mao [45] showed that kaempferol, naringenin, wogonin, neobaicalein in Jinhua Qinggan granules well docked with specific target proteins of SARS-CoV-2.

The core target proteins such as AKTI, HSP90AA1, ELA, IL6, TNF, and MAPKs are mainly related to inflammation and immunoregulation.

Li [46] reported that Lianhua Qinwen markedly reduced pro-inflammatory cytokines (TNF-α, IL-6, CCL-2/MCP-1, and CXCL-10/IP-10) production in a concentrationdependent manner in SARS-CoV-2 infected Huh-7 cells at the mRNA levels by realtime quantitative PCR assays. Wang [47] Ling [48] and Wang [50] Besides, Shi [51] , He [52] , and Kong [53] speculated that Xuebijing injection played an anti-inflammatory effect by NF-κB, VEGF, HIF-1, IL17, and PI3K-Akt signal pathway. By molecular docking and network analysis, Han [60] showed that ophiopogonins, ginsenosides, and sanchinoside Rd might be the main ingredient of Shenmai injection to treat COVID-19 by targeting on IL-6, IL-2, and TNF.

ACE2 can catalyze the splitting of angiotensin (Ang) Ⅰ and Ang Ⅱ into Ang (1-9) and

Ang (1-7), respectively, and regulate ACE2-Ang (1 -7)-Mas axis to protect the acute lung injury [66] . However, ACE2 is also a cell receptor of SARS-CoV-2 in the human J o u r n a l P r e -p r o o f body. [68] The combination of SARS-CoV-2 and ACE2 [69] disrupts the balance between Ang Ⅰ/ Ang Ⅱ and Ang (1-9)/Ang (1-7), thereby generate many free radicals, which can change the permeability of cell membranes and lead to the organ damages.

ZHOU [70] speculated that SARS-CoV-2 could infect type Ⅱ alveolar epithelial cells through ACE2, thus destroying the lung tissue and air-blood barrier. Then, the virus continued to infect other organs through ACE2, such as the heart, kidneys, and liver by blood circulation. It further triggered an excessive immune response, such as the imbalance of T-helper-1 (Th1) and Th2 cells, which produced numerous inflammatory cytokines, causing a cytokine storm and leading to MODS ultimately. CMs can play a direct or indirect role in protecting target organs by inhibiting the binding of the virus to ACE2 to produce anti-inflammation, anti-oxidation, anti-fibrosis, and expectorant action [71] . [45] found that Jinhua Qinggan granules played a role in regulating apoptosis via PI3K-Akt, MAPK, and Ras pathways. Ling [48] reported that 18β-glycyrrhetinic acid, stigmasterol, indigo, β-sitosterol, luteolin, quercetin and naringenin in Lianhua Qingwen Prescription might target on ACE2 and protect the target organs of COVID-19 through the renin-angiotensin pathway. Xu [56] predicted that MAPK8, MAPK1, MAPK14, FOS, CASP3, endocrine resistance, EGFR tyrosine kinase resistance, platinum drug resistance, antifolate resistance, arginine biosynthesis, and MAPK signaling pathways could be involved in the inhibition of cell apoptosis and pulmonary fibrosis by Shufeng Jiedu capsule.

From the above-reviewed researches, we can see that there are some ingredients and action mechanisms in common for these CMs used for treating COVID-19, which could be important for these CMs to exert their effect and drug development. Therefore, we further calculate the frequencies of these ingredients and action mechanisms that appeared in these reports. The results ( Table 2) China and generated some useful information, these researches only analyzed these formulae and medications individually. The results of these researches could reflect more on the unique features of individual formula and medication and less on the general features of these formulae and medications. To understand the general features of these formulae and medications, we selected TMTD to screen the common components and then analyzed the targets and signaling pathways that these components may act on using networking analysis. The common components of TMTD were generated by using the SymMap database (https://www.symmap.org/) and TBtools software (V0.665). The results (Fig. 2) shows that there are total 401 compounds in TMTD, of which ten compounds are shared by the six formulae of TMTD, they are ursolic acid, thymol, sucrose, rutin, physcion, oleanolic acid, caffeic acid, β-terpinene, β-sitosterol, and β-elemene. We believe that the common action mechanisms of TMTD also lies in these ten compounds. Therefore, we further predicted the possible targets and signaling pathways that the ten compounds may act on by network pharmacology analysis. The results shown that the potential targets are FGF2, (Fig. 3) . The network shows that the common action mechanisms of TMTD in the treatment of COVID-19 could be related to signal transduction, immune system, and cell growth and death.

By comparing the results of above two strategies of network pharmacology analysis on the useful formulae and medications of TCM in treating COVID-19, we found that although the common compounds are different, the possible action mechanisms are overlapped with each other, implying that different compounds may act on same or similar targets or pathways. This inference gives TCM redundant mechanisms to treat diseases and also explains why different TCM formulae with different composition can treat the same disease.

Taken together, the practice in controlling the outbreak in China has proved the clinical 

HZ and YX supervised all research and revised the manuscript. YFH and FH collected information. CB performed networking analysis. YFH and HZ analyzed the data and prepared the manuscript.

The authors declare that there are no conflicts of interest.

The authors declare no conflicts of interest. Purple arrows: CMs also has an expectorant effect of relieving airway obstruction. Green pies: the node group of targets. Purple pies: the node group of signal pathways.

Orange pies: the node group of mechanism classifications. 

COVID-19 exceeds 90%, People's Daily Overseas Edition

Treatment Efficacy Analysis of Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19): An Empirical Study From Wuhan

Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb

Chinese plays a role in the prevention and on novel coronavirus pneumonia

Clinical Efficacy Analysis of 50 Cases of COVID-19 in Traditional Chinese Medicine

Retrospective Clinical Analysis on Treatment of Novel Coronavirus-infected Pneumonia with Traditional Chinese Medicine Lianhua Qingwen

Arbidol Hydrochloride Capsules in the treatment of COVID-19

Traditional Chinese Medicine to Brighten New Coronavirus Pneumonia--The Significance and Role of the State pharmacology and molecular docking

COVID-19) with Jinhua Qinggan Granules Based on Network Pharmacology and Molecular Docking

Based on Network Pharmacology and High-Throughput Molecular Docking to Study the Potential Molecular Mechanism of Active Compounds Tthat Bind SARS-Cov

Specific Target Protein in Jinhua Qinggan Granules to Interfere with COVID-19, Modernization of Traditional Chinese Medicine and Materia Materia-World Science and Technology

Jinhua Qinggan Granule in the Treatment of Novel Coronavirus Pneumonia

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2), Pharmacological research

Study on the Network Pharmacology and Preliminary Evidence of Lianhua Qingwen in the of novel coronavirus (2019-nCoV) Pneumonia

Exploring material basis and mechanism of

Lianhua Qingwen Prescription against coronavirus based on network pharmacology

Theoretical Study of the anti-NCP Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (LQF)

Clinical Efficacy and Mechanism of Lianhua Qingwen Granule on COVID-19 Based on

Study on the overall regulation of Xuebijing injection in treating corona virus disease

Potential Mechanism of Xuebijing Injection in Treatment of Coronavirus Pneumonia Based on Network Pharmacology and Molecular Docking

Exploring the Mechanism of Xuebijing Injection in Treating COVID-19 Based on Network Pharmacology

network pharmacologic molecular mechanism of Shenmai Injection in treatment of COVID-19 combined with coronary heart disease

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3), Evid Based

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Analysis on the application of Traditional Chinese Medicine in the treatment of COVID-19 by suppressing cytokine storm, Chinese Traditional and Herbal Drug

Sini decoction ameliorates sepsis-induced acute lung injury via regulating ACE2-Ang (1-7)-Mas axis and inhibiting the MAPK signaling pathway

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Renin-angiotensin system and diabetic cognitive dysfunction, and effects of traditional Chinese medicine on Them

Mechanistic investigation of multiple organ dysfunction syndrome induced by 2019 novel coronavirus

Effective Chinese Medicine for Treatment of Novel Coronavirus Pneumonia based on Renin-Angiotensin System

Network-based drug discovery by integrating systems biology and computational technologies